Allurion Technologies Announces New Clinical Data on the Elipse® Balloon at ObesityWeek® 2020
10.11.2020 15:00:00 EET | Business Wire | Press release
Allurion Technologies, a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced new clinical data on the Elipse Balloon at ObesityWeek 2020. The Allurion Program features the Elipse Balloon, the world’s first and only procedureless weight loss device. The balloon is designed to remain in the stomach for 4 months and is paired with a Bluetooth® connected scale and Allurion smartphone app and a supervised nutritional program.
In Long-Term Efficacy of the Elipse Gastric Balloon System: An International Multicenter Study, Dr. Roberta Ienca and colleagues report on 509 patients who received the Elipse Balloon and were followed for one year. After 4 months of Elipse Balloon treatment patients achieved weight loss of 14.4 ± 7.7kg or 13.9 ± 6.4% of total body weight. At one-year follow-up, 95% of this weight loss was sustained.
In Sequential Elipse Balloon Treatment: 1-Year Weight Loss Results Approximates Bariatric Surgery Results, Dr. Roberta Ienca and colleagues report on 42 patients treated with sequential Elipse Balloons. Between one and five months following the passing of the first Elipse Balloon, a second balloon was placed. After 4 months, mean weight loss and percent total body weight loss were 14.7 ± 4.4kg and 14.4 ± 3.6%, respectively. The second balloon resulted in an additional 8.8 ± 5.7kg and 10.0 ± 6.5% weight loss, respectively. In total, sequential balloon treatment resulted in weight loss of 22.0 +/- 9.0kg or 22.8 +/- 8.8%, and a body mass index (BMI) decrease of 8.1kg/m2 from baseline.
“Both of these studies demonstrate the potential that the Allurion Program has in providing consumers with long-term and sustainable results,” said Dr. Shantanu Gaur, co-founder and CEO of Allurion. “Additionally, this data indicates that consumers can achieve life-changing results without needing to undergo surgery, endoscopy or anesthesia.”
“The Elipse Balloon provides my patients with a primary weight loss tool and an alternative to weight loss surgery,” said Dr. Alberto Pagan, Clinica CINIB, Palma de Mallorca, Spain. “These results underscore how the Allurion Program can deliver both short and long-term results that meet the expectations of my patients.”
“The clinical data presented at Obesity Week is reflective of the increasing demand for our product around the world,” said Benoit Chardon, Executive Vice President Commercial for Allurion. “We have tripled the number of patients treated in the past year and have created a reputation for clinical results that providers and patients can trust.”
About Allurion Technologies
Allurion Technologies is dedicated to helping people realize their full potential with innovative, scalable and trusted experiences. The company's flagship product, the Allurion Program, is a 360-degree weight loss experience featuring the Elipse Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss. Learn more about the Elipse Balloon and Allurion online at www.allurion.com, on Facebook at www.fb.com/allurion or on Twitter @alluriontech.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005027/en/
Contact information
Whitney Cypes
+1 (408)-547-7531
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi's Research Leadership Recognized Across Leading Scientific Organizations16.6.2026 16:00:00 EEST | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced recognitions received by Dr. Edward Rothberg and Dr. Andreas Wächter from leading academic and industry organizations for research that has had lasting impact on the field of optimization. “Gurobi was founded on a commitment to rigorous, applied optimization research,” said Dr. Oliver Bastert, CTO, Gurobi. “And these recognitions are a reflection of that legacy. The foundational work that Ed and Andreas produced continues to shape the field, and that same spirit of scientific innovation drives everything we do today.” Dr. Edward Rothberg, co-founder and Chairman of the Board at Gurobi, was recently honored with the INFORMS Test of Time Paper Award for his paper, “An Evolutionary Algorithm for Polishing Mixed Integer Programming Solutions.” The paper introduced a novel approach to finding high-quality solutions to difficult MIP problems — expanding what was possible within the MIP framework and inf
New CSC Report Illustrates How AI Is Affecting Enterprise Security Leaders16.6.2026 16:00:00 EEST | Press release
CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and domain name system (DNS) threats, today released new research on how chief information security officers (CISOs) are adapting to an evolving artificial intelligence (AI) ecosystem while managing traditional cyber threats, such as DNS outages. According to CSC’s CISO Outlook 2026 report, 73% of respondents say AI presents more of an opportunity than a risk for cybersecurity. However, these security leaders continue to face challenges in addressing attacks, including AI-powered domain generation algorithms (DGAs), which 86% of respondents cite as a threat. To thoroughly understand the CISO perspective on today’s cybersecurity landscape, CSC surveyed 300 senior executives—including CISOs, chief technology officers (CTOs), chief information officers (CIOs), and heads of cybersecurity—in Q1 2026. Key findings from the CISO Outlook 2026 report include: Respondents ranked the top three threats i
Airship Helps DIE ZEIT Turn Silent Advocates into 4.9-Star Rating16.6.2026 16:00:00 EEST | Press release
Airship, the mobile-first customer experience company, today announced that DIE ZEIT, one of Germany’s largest and most prestigious publishers, has successfully transformed its mobile app presence, lifting the Google Play app store rating from 2.7 stars in early 2026 to a near-perfect 4.9 stars. At a time when many traditional publishers are seeing readership numbers plummet, DIE ZEIT is growing — reaching an all-time high circulation in 2025 and building a digital ecosystem around the brand. The majority of the publication’s readers are now digital, but the publication’s app store rating for DIE ZEIT didn’t match this momentum. DIE ZEIT was up against a universal challenge faced by digital product teams and customer experience executives globally: the "silent advocate" problem. While highly satisfied customers rarely pause their reading experience to leave public reviews, users facing temporary, one-off frustrations are highly motivated to voice complaints. This discrepancy often lead
Clearlake Capital Closes on $14.8 Billion to Capitalize on AI-Driven Transformation and Continue Sector-Focused Investment Strategy16.6.2026 16:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced the successful close of its eighth flagship fund, Clearlake Capital Partners VIII (“Fund VIII”), alongside related co-investment vehicles and separately managed accounts. Together, these vehicles represent $14.8 billion of capital commitments and position Clearlake to continue investing behind the secular trends reshaping industries, including artificial intelligence, software modernization, digital transformation, and operational efficiency. The successful fundraise comes amid a highly competitive and selective fundraising environment for private markets and underscores continued investor confidence in Clearlake's differentiated sector-focused strategy, integrated investment platform, and proven ability to create value across market cycles. The close was supported by a diverse
TestMu AI Introduces DevTools Assertions in Kane CLI, Enabling Browser-Level Validation Through Natural Language16.6.2026 15:30:00 EEST | Press release
TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced DevTools Assertions for Kane CLI, enabling developers and AI agents to validate browser internals using natural language. Traditional browser automation focuses on what users can see: buttons, forms, text, and visual states. However, modern web applications depend heavily on browser activity that remains invisible to users, including network requests, API responses, console logs, cookies, local storage, and performance metrics. With DevTools Assertions, Kane CLI extends browser validation beyond the UI, allowing teams to verify these underlying signals using plain-English objectives. Developers can now write objectives such as: "Click Add to Cart and assert the request to /api/cart returned status 200." "Run the checkout flow and assert the console has no errors." "Log in and store the session cookie value." "Assert localStorage contains the selected product ID." "Open th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom